Beauty Health (NASDAQ:SKIN – Get Rating) had its price target dropped by investment analysts at DA Davidson from $35.00 to $24.00 in a note issued to investors on Wednesday, The Fly reports. DA Davidson’s price target points to a potential upside of 92.00% from the stock’s current price.
Several other equities research analysts have also recently commented on the stock. Zacks Investment Research raised shares of Beauty Health from a “hold” rating to a “buy” rating and set a $21.00 price target on the stock in a research report on Saturday, February 26th. JPMorgan Chase & Co. started coverage on shares of Beauty Health in a report on Friday, March 11th. They issued an “overweight” rating and a $24.00 target price on the stock. Piper Sandler dropped their target price on shares of Beauty Health from $26.00 to $24.00 in a report on Wednesday. Finally, Benchmark upped their price target on shares of Beauty Health from $18.00 to $23.00 and gave the company a “buy” rating in a research note on Monday, March 14th. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $25.90.
SKIN opened at $12.50 on Wednesday. Beauty Health has a 12 month low of $10.73 and a 12 month high of $30.17. The firm’s fifty day simple moving average is $15.85 and its 200 day simple moving average is $19.27. The company has a quick ratio of 12.63, a current ratio of 13.09 and a debt-to-equity ratio of 2.41.
Beauty Health (NASDAQ:SKIN – Get Rating) last posted its quarterly earnings data on Tuesday, February 22nd. The company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.04. The company had revenue of $77.90 million during the quarter, compared to the consensus estimate of $70.90 million. The firm’s quarterly revenue was up 106.1% on a year-over-year basis. On average, research analysts predict that Beauty Health will post 0.09 earnings per share for the current year.
Several hedge funds and other institutional investors have recently modified their holdings of SKIN. The Manufacturers Life Insurance Company lifted its position in shares of Beauty Health by 68.7% during the third quarter. The Manufacturers Life Insurance Company now owns 43,217 shares of the company’s stock valued at $1,122,000 after purchasing an additional 17,594 shares in the last quarter. Bluestein R H & Co. bought a new stake in shares of Beauty Health in the 3rd quarter worth approximately $390,000. Wellington Management Group LLP bought a new stake in shares of Beauty Health in the 3rd quarter worth approximately $35,426,000. Goldman Sachs Group Inc. lifted its holdings in shares of Beauty Health by 633.5% in the 3rd quarter. Goldman Sachs Group Inc. now owns 421,745 shares of the company’s stock worth $10,952,000 after acquiring an additional 364,248 shares during the last quarter. Finally, Lord Abbett & CO. LLC bought a new stake in shares of Beauty Health in the 3rd quarter worth approximately $56,687,000. Hedge funds and other institutional investors own 72.01% of the company’s stock.
Beauty Health Company Profile (Get Rating)
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company’s flagship product includes HydraFacial that enhance the skin to cleanse, peel, exfoliate, extract, infuse, and hydrate the skin with proprietary solutions and serums.
Read More
Receive News & Ratings for Beauty Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Beauty Health and related companies with MarketBeat.com’s FREE daily email newsletter.
DA Davidson Trims Beauty Health (NASDAQ:SKIN) Target Price to $24.00